CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

PHASE3CompletedINTERVENTIONAL
Enrollment

1,725

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

May 31, 2007

Conditions
Ulcerative Colitis
Interventions
DRUG

OPC-6535

DRUG

Asacol®

Trial Locations (26)

11021

Long Island Clinical Research Associates, Great Neck

20815

Metropolitan Gastroenterology Group, Chevy Cha

21404

Digestive Disorders Associates, Annapolis

23149

McGuire DVAMC, Richmond

27262

Bethany Medical Center, High Point

28207

Charlotte Gastroenterology & Hepatology, Charlotte

28401

Hanover Medical Specialists, PA, Wilmington

28801

Asheville Gastroenterology Associates, Asheville

29425

Medical University of South Carolina, Charleston

32256

Borland-Groover Clinic, Jacksonville

33021

Mark Lamet, Hollywood

33542

Florida Medical Clinic, Zephyrhills

34684

Advanced Gastroenterology Associates, Palm Harbor

35801

Clinical Research Associates, Huntsville

37660

Gastroenterology Associates, Kingsport

38801

Digestive Health Specialists, PA, Tupelo

45440

GI & Liver Consultants, Dayton

48047

Clinical Research Institute of Michigan, LLC, Chesterfield

65265

Center for Digestive and Liver Diseases, Mexico

73112

Sooner Clinical Research, Oklahoma City

74135

Healthcare Research Consultants, Tulsa

78229

Gastroenterology Clinic of San Antonio, San Antonio

84405

Advanced Research Institute, Ogden

90045

West Gastroenterology Medical Group, Los Angeles

02184

Coastal Research Associates, Braintree

08234

Atlantic Gastroenterology Associates, PA, Egg Harbor

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT00092508 - CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission | Biotech Hunter | Biotech Hunter